Recently sibutramine was taken off the market because of its cardiovascular effects, while Orlistat has been associated with isolated cases of fulminant hepatic failure.
Recientemente, la sibutramina fue retirada del mercado por sus efectos cardiovasculares y el orlistat se ha asociado en casos aislados con falla hepática fulminante.